The combination of gefitinib with an AKT inhibitor (perifosine) or PAK1 inhibitor (IPA-3) almost completely suppresses the tumor burden in nude mice harboring gefitinib resistant cells [20]. The gene discussed is AKT1; the disease is neoplasm.